PharmiWeb.com - Global Pharma News & Resources

PwToday Stories

Responding to news that Sir. Andrew Dillon is to step down as NICE CEO in March next year, ABPI CEO Mike Thompson said: "He has played a central role in building the credibility of the organisation, insisting on transparent processes, and a continuous dialogue with all stakeholders, recognising that as the science evolves, NICE needs to evolve too.  As a result of this leadership, there is a consensus across industry about the central role of NICE in assessing all medicines, ensuring that patients have a right to access the treatments they need. Hugely respected by all, we thank and congratulate Andrew on his outstanding achievements at NICE, and we wish him all the very best in his future endeavours”.
The NHS has saved hundreds of people from sepsis thanks to better use of digital technology in hospitals. In a major nationwide push to tackle the condition, including a one hour identification and treatment ambition, new ‘alert and action’ technology is being introduced which uses algorithms to read patients’ vital signs and alert medics to worsening conditions that are a warning sign of sepsis. Sepsis – also known as blood poisoning – is a life-threatening response to an infection in the body, where the immune system damages tissues and organs. Three leading hospitals are using alerts to help identify sepsis and tell doctors when patients with the serious condition are getting worse, ahead of the measures being rolled out across England as part of the NHS Long Term Plan. NHS leaders in C…
A study conducted at the University of Eastern Finland demonstrated that a recently described T-cell subset, so-called peripheral T helper cells, may have a role in the development of type 1 diabetes. The frequency of circulating peripheral T helper cells was observed to be increased both in children with recently diagnosed type 1 diabetes and in healthy children who later progressed to type 1 diabetes. The study was published in the journal Diabetologia. Type 1 diabetes is an autoimmune disease that typically manifests in childhood. In type 1 diabetes, insulin-producing beta cells in the pancreas are destroyed by the immune system. In addition to genetic susceptibility, the appearance of autoantibodies in blood is predictive of future development of type 1 diabetes. The appearance of auto…
An innovative partnership is transforming the lives of young people with learning disabilities in London. Ten students have recently graduated through the collaboration between DFN Project SEARCH and Moorfields Eye Hospital NHS Foundation Trust with four graduates already in full-time employment. 1000 young people have now graduated and secured full-time employment through DFN Project SEARCH programmes in the UK. DFN Project SEARCH CEO Maura Lynch said: “Our partnership at Moorfield’s Eye Hospital is changing lives for the better.” __________________________________________________________________________________ An innovative partnership is helping to change the lives of young people with learning disabilities in London. DFN Project SEARCH is working with Moorfield’s Eye Hospital to trans…
More than 150,000 members of the public and more than 50 health leaders are calling on Prime Minister Boris Johnson to take action now to address the escalating crisis in care.   In what is believed to be the largest petition of its kind, the Prime Minister is urged to end the swingeing cuts in social care that have left around 1.4 million older people in England unable to access the care and support they need.   In a letter to the Prime Minister, NHS leaders welcome his commitment to ‘fix the crisis in social care once and for all’. They have pledged their support and are calling for:  Cross-party talks to help deliver a more sustainable social care system, backed up by a long-term financial settlement.  Immediate funding increases in the upcoming one-year government spending review that…
Responding to the latest NHS performance statistics, Nick Ville, director of membership and policy at the NHS Confederation, said: “These figures show the health service is still struggling to climb out of the morass created by a decade of austerity. Year on year, the demands made on frontline services continue to grow, with attendances at A&E significantly higher than at this time last year. Our dedicated staff do all they can for patients, but they are being stretched to breaking point.“This week’s announcement of additional investment in the NHS is welcome, as the money is desperately needed to modernise services and to improve the quality and efficiency of patient care. But the government must complete the ‘unfinished business’ of the funding settlement for the health and care syst…
In Vitro Approach Provides Predictive Platform for Human-Based Drug Discovery NEW YORK, August 6, 2019 (Newswire.com) - ​​​​Researchers from TARA Biosystems, Inc. and GlaxoSmithKline (GSK) today published data demonstrating that TARA’s engineered heart-on-a-chip system replicated drug responses found in adult humans. The findings, published in the Journal of Toxicological Sciences, show TARA’s 3D-cardiac tissue platform can predict how human hearts will respond to a wide range of drugs, something that has been a challenge in pre-clinical models until now. “The cardiac tissues generated in the study are the first to provide high-fidelity human drug responses and demonstrate the potential for evaluating the safety and efficacy of new therapies in preclinical development,” said Michael P. Gra…
Timothy Kulbago named one of the most inspiring people in life sciences industry PHILADELPHIA – Aug. 5, 2019 – ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced that Timothy Kulbago, Vice President, Imaging has been named one of the 100 most inspiring individuals in the life-sciences industry by PharmaVoice. Representing a broad cross-section of industry sectors, the PharmaVoice 100 honorees are selected based on how they have inspired their colleagues and affected positive changes in their organizations, as well as their involvement in community and philanthropic activities. “We’re pleased to honor Tim as he truly represents the spirit of the PharmaVoice 100,” said Taren Grom, Editor and Cofounder of PharmaVOICE. “His contr…
Supporting the NHS on its decade-long journey towards an integrated health and care system, as well as delivering extra investment for new buildings and infrastructure, social care and addressing major gaps in NHS staffing, should be at the top of the new Prime Minister’s priority list. That is the call today from the NHS Confederation in a letter and briefing to the Prime Minister. The NHS Confederation, which represents organisations across the healthcare sector, says there is much ‘unfinished business’ for the new government to resolve in the health and care sector. The letter warns the Prime Minister that the question of NHS funding is not yet settled, despite the £20.5bn funding settlement that kicked in from April this year. The settlement excluded some vital areas of expenditure tha…
MR Solutions has received the prestigious Queen’s Award for Enterprise in recognition of the company’s innovative PET imaging technology for use in pre-clinical research. MR Solutions already holds Queens Awards for innovation in 2016 and for export achievement in 2017. MR Solutions has been the world leader in new developments in pre-clinical scanning firstly with the world’s first liquid helium free high field scanners and secondly the introduction of multi-modality scanners incorporating MRI with PET or SPECT and CT with PET or SPECT. The Queens award was for the PET module which used the latest technology in silicon photomultipliers. This advanced technology improved performance and substantially shrank the size of the PET scanner.  MR Solutions’ PET scanner can now be inserted within…
GlaxoSmithKline plc (GSK) today announced that Jonathan Symonds will succeed Sir Philip Hampton as Non-Executive Chairman of the GSK Board with effect from 1st September 2019. Jonathan is currently Deputy Group Chairman of HSBC Holdings plc and has been an independent non-executive Director of HSBC since April 2014. He is a former Chief Financial Officer of Novartis AG and AstraZeneca plc, and has been a non-executive Director of Diageo plc and QinetiQ plc. He is currently non-executive Chairman of Proteus Digital Health Inc, a non-executive director of Rubius Therapeutics Inc and Chairman of Genomics England Limited. The appointment was approved by the Board and follows a thorough succession process undertaken by the Nominations Committee, led by Vindi Banga, the company’s Senior Independ…
NEW YORK, July 22, 2019 (Newswire.com) - ​​​​​InvestAcure, PBC, honored 10 leading bioindustry scientists with the Cure Coin Award for their outstanding work developing groundbreaking scientific discoveries into lifesaving therapeutics for Alzheimer's, CTE and other related Dementias. The award reception took place on July 15, during the 2019 Alzheimer's Association International Conference in Los Angeles.  "The Cure Coin Award aims to bring public attention to the vital work of leading industry scientists developing lifesaving treatments," said Max Tokarsky, the founder and CEO of InvestAcure, a Public Benefit, Finance company building a spare-change investment platform to facilitate public investment in companies working on developing effective therapeutics for Alzheimer’s.  While govern…
Converse Pharma Group is primed for national expansion after securing a £60m combined facility from Royal Bank of Scotland (RBS) and Secure Trust Bank Commercial Finance. Founded in 2013, the firm is a national pharmaceutical wholesaler, providing a comprehensive range of prescription drugs to over 5,500 independent pharmacies across the UK and Ireland. Operating from bases in Doncaster and Prudhoe, Converse Pharma Group currently employs 980 members of staff across its 12 sites in the UK and Ireland. Its 140 strong sales team has helped revenues increase sharply in recent years, having achieved sales of £250m in 2018 – up from £188m the previous year. The funding provided by RBS and Secure Trust Bank will enable the company to invest in new, larger depots, increasing the depth and range o…
Scientists at the University of Eastern Finland and the University of Oxford have shown that small RNA molecules occurring naturally in cells, i.e. microRNAs, are also abundant in cell nuclei. Previously, microRNAs were mainly thought to be found in cytoplasm. The scientists also discovered that microRNA concentrations in cell nuclei change as a result of hypoxia. The findings strongly suggest that microRNAs play a role in the expression of genes in the cell nucleus. This observation is crucial for the development of novel gene therapy, among other things. The study was published in Scientific Reports today. The scientists profiled the division of microRNAs in different parts of endothelial cells, discovering that a large share of microRNAs are enriched in cell nuclei. When the scientists…
Today, Galapagos announces transformational multi-billion dollar collaboration with Gilead to create a global R&D leader based in Europe, developing and commercialising breakthrough therapies to patients. Please see the press releases https://www.glpg.com/press-releases Multi-billion dollar collaboration is one of the largest ever biotech deals in Europe - $3.95 billion upfront payment, a $1.1bn equity investment by GILD, $1.1bn additional opt-in payments for two late stage products, as well as additional milestones to access early pipeline assets, and double digit royalties. Creates a global R&D leader - Collaboration will accelerate GLPG’s vision to become a top 10 global biotech company and establish global leadership in inflammation & immunology. GLPG’s enhanced financial…
Novartis, Amgen and Banner Alzheimer's Institute today announced the decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase II/III studies in the Alzheimer's Prevention Initiative Generation Program. An assessment of unblinded data during a regular pre-planned review identified worsening in some measures of cognitive function. Given these findings, the sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk. John Tsai (M.D.), Head of Global Drug Development and Chief Medical Officer, said: "Novartis has a strong research focus and commitment to patients. As researchers we have to accept today's disappointing news as part of the search for innovative new treatments. We remain committed to advanci…
Commenting on the government response to the Promoting professionalism, reforming regulation consultation, Danny Mortimer, chief executive of NHS Employers, said: “Employees and employers will welcome steps to make the fitness to practise process quicker, fairer and effective; they will also look forward to further reform, which will allow the regulation of new roles and professions to support their full deployment to care for our patients.”
The Government will announce further details for how they will support pharmaceutical companies’ investments in the development of drugs that will treat AMR infections. The NHS will test a first-of-its-kind ‘subscription-style’ payment model that will help incentivise companies to develop new drugs needed to tackle resistant infections. The ABPI welcomes further detail on the Government’s approach. Dr Sheuli Porkess, Executive Director of Research, Medical and Innovation at the Association of the British Pharmaceutical Industry (ABPI), said:“Increased resistance to antibiotics is one of the greatest threats to global health we face. “Today’s announcement is an example of how the UK can lead the world in this fight and hopefully brings us closer to fixing the problems that have hampered inv…
• Strategic partnership between world’s leading cancer research charity and leading specialist healthcare investment firm with track record of creating breakthrough companies and treatments • Major opportunity to progress charity’s research and translate scientific breakthroughs into new cancer medicines for patients• US$25 million investment by Cancer Research UK into new life sciences investment fund• Cancer Research UK to collaborate closely with SV Health Investors to identify research within charity’s network that could be rapidly developed London, July 2nd 2019, Cancer Research UK, the world's largest independent funder of cancer research, today announced a strategic partnership with SV Health Investors (SV), a leading life sciences venture capital and growth equity firm, focused on…
On June 25, 2019, AbbVie Inc. and Allergan announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie's common stock of $78.45 on June 24, 2019. Strategic Rationale: New growth platforms and leadership positions to diversify and expand revenue base: The combined company will consist of several attractive franchises with leadership positions across immunology, hematologic oncology, medical aesthetics, neuroscience, women's health, eye care and virology.  Allergan's product portfolio will be enhanced by AbbVie's commercial strength, expertise and international infrastructure. Immediate scale and en…